お知らせ • Apr 17
Myriad Genetics Announces Six Abstracts and Podium Presentations at AACR Annual Meeting
Myriad Genetics, Inc. announced that it will share six abstracts, including two podium presentations, at the American Association for Cancer Research Annual Meeting 2026. The company will share new results from the MONITOR-Breast study, a prospective, multi-center clinical trial evaluating the performance of Precise MRDTM in breast cancer across all phases of the treatment journey. The data will be shared in a podium presentation on Monday, April 20, 2026 by Dr. Julia Foldi, MD, PhD, University of Pittsburgh Medical Center Hillman Cancer Center. These results expand on the study's early insights presented at the San Antonio Breast Cancer Symposium in December 2025, including results from a large cohort of patients receiving neoadjuvant therapy with frequent MRD assessment, providing the first high-temporal resolution characterization of ctDNA dynamics in all breast cancer subtypes during neoadjuvant treatment. Additionally, Dr. Ranjan Upadhyay from The University of Texas MD Anderson Cancer Center will present the results of a phase II clinical trial. Together, these results from clinical trials continue to build and expand the evidence supporting the performance of the Precise MRD test in breast cancer treatment and surveillance. The following abstracts will be presented at the American Association for Cancer Research Annual Meeting on April 17-22, 2026, at the San Diego Convention Center in San Diego. Myriad Genetics Presentations Session CTMS04 - Focus on ctDNA Early findings from MONITOR-Breast: ctDNA dynamics during neoadjuvant therapy using an ultrasensitive MRD assay Podium; Abstract Presentation Number: CT171 Mon., April 20 – 2:50 - 3:00 pm, Hall H - Ground Level - Convention Center Presenter: Julia Foldi, MD, PhD, University of Pittsburgh Medical Center Session CTMS04 - Focus on ctDNA A phase II trial of adjuvant PD-1 blockade with endocrine therapy in hormone receptor positive inflammatory breast cancer: Circulating biomarkers and molecular correlates of clinical outcomes Podium; Abstract Presentation Number: CT172 Mon., April 20 – 3:05 - 3:15 pm PST, Hall H - Ground Level - Convention Center Presenter: Ranjan Upadhyay, MD, PhD, The University of Texas MD Anderson Cancer Center Liquid Biopsies: Circulating Nucleic Acids 2 Analytical validation of an ultra-high sensitivity tumor-informed MRD assay Poster Board Number: 2598 Mon., April 20 – 9:00 am - 12:00 pm PST Presenter: Ashley Acevedo, PhD, Myriad Genetics Genetic Epidemiology 1: GxE, GWAS, Polygenic Risk Scores, and Post-GWAS Independent validation of polygenic risk scores for overall and triple-negative breast cancer among high-risk African American women Poster Board Number: 3587 Mon., April 20 – 2:00 – 5:00 pm PST Presenter: Dezheng Huo, PhD, University of Chicago Liquid Biopsies: Circulating Nucleic Acids 4 Fragmentomic analysis of cfDNA WGS at regulatory regions generates gene-level expression-like traits for subtype analysis in breast cancer Poster Board Number: 5313 Tues, April 21 – 9:00 am – 12 pm PST Presenter: James Davison, PhD, GeneCentric Therapeutics, Inc. Phase I and Phase II Clinical Trials in Progress A pragmatic study of the clinical utility of genomic classifiers in guiding prostate cancer treatment decisions: Impact of treatment selection, oncologic outcomes, and treatment-related adverse events (PROMPT-Bx) Poster Board Number: 14; Abstract Presentation Number: CT280 Tues., April 21 – 2:00-5:00 pm PST Presenter: Matthew Schiewer, PhD, Myriad Genetics Myriad tests to be highlighted at the conference booth include: Precise MRD (Molecular Residual Disease) Test is a tumor-informed assay that uses whole genome sequencing (WGS) to achieve ultra-sensitivity. This unique assay enables the custom selection of up to 1,000 targeted variants for deep analysis. It has impressive limits of detection and sensitivity. The test can be used to monitor circulating tumor DNA (ctDNA) levels throughout a patient’s clinical cancer care, starting immediately after diagnosis and continuing through treatment and surveillance. MyRisk Hereditary Cancer Test with RiskScore combines genetics, clinical factors (Tyrer-Cuzick), and polygenic risk to uncover insights that gene testing alone may not provide, helping offer more information to support patient decisions in breast cancer risk assessment and management. Prolaris Prostate Cancer Prognostic Test is a molecular diagnostic test that provides personalized information about the aggressiveness of a patient’s prostate cancer, helping to identify whether it is safe to forgo treatment, whether to pursue treatment, and how much treatment is needed for the best possible outcome. Prolaris is the only biomarker test to quantify the benefits of adding androgen ADT to RT. The booth will feature Myriad’s Biopharma services which are utilized for working in conjunction with Biopharma partners to advance drug development programs from biomarker discovery through CTA, CDx development, worldwide regulatory approval and global commercialization, including: MyChoice CDx is the only FDA-approved homologous recombination deficiency (HRD) test specifically mentioned in ASCO guidelines for selecting patients with ovarian cancer who may benefit from PARP inhibitors. By determining comprehensive HRD status, the MyChoice CDx Test helps expand access to targeted therapy in both early and late-line settings. MSK-ACCESS is a comprehensive liquid biopsy test developed by Memorial Sloan Kettering Cancer Center (MSK). The test offers noninvasive cancer genomic profiling and disease monitoring using cell-free DNA (cfDNA) obtained from blood and other body fluids. The test is currently available for use in conjunction with Myriad’s Pharma partnerships for CTA development and CDx utilizing Myriad’s partnership with SOPHiA GENETICS. MSK-IMPACT is a solid tumor test for comprehensive genomic profiling (CGP) which delivers high-resolution profiling of complex biomarkers from DNA and RNA in a single, end-to-end workflow.